Skip to main content

Table 2 Indirect comparison of overall survival

From: Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

HR of OS (95% CI)
GEM
 2.03 (1.63–2.54) * GEM-NAB   
 2.19 (1.77–2.71) * 1.08 (0.92–1.25) FOLFIRINOX  
 2.29 (1.55–3.40) * 1.13 (0.78–1.63) 1.05 (0.75–1.47) mFOLFIRINOX
  1. Abbreviation: HR: hazard ratio; OS: overall survival; CI: confidence interval; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX
  2. Notes: Comparisons between treatments were read from left to right, and the estimate (HR) with 95% CI for a given comparison was read in the intersection of two treatments. The value of estimates higher than 1 indicated that column-defining treatment had better efficacy
  3. * Denotes p-value < 0.05